The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study
- 5 April 2007
- journal article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 52 (9), 2387-2395
- https://doi.org/10.1007/s10620-006-9703-2
Abstract
Oxidative stress leads to chronic liver damage. Silybin has been conjugated with vitamin E and phospholipids to improve its antioxidant activity. Eighty-five patients were divided into 2 groups: those affected by nonalcoholic fatty liver disease (group A) and those with HCV-related chronic hepatitis associated with nonalcoholic fatty liver disease (group B), nonresponders to treatment. The treatment consisted of silybin/vitamin E/phospholipids. After treatment, group A showed a significant reduction in ultrasonographic scores for liver steatosis. Liver enzyme levels, hyperinsulinemia, and indexes of liver fibrosis showed an improvement in treated individuals. A significant correlation among indexes of fibrosis, body mass index, insulinemia, plasma levels of transforming growth factor-β, tumor necrosis factor-α, degree of steatosis, and γ-glutamyl transpeptidase was observed. Our data suggest that silybin conjugated with vitamin E and phospholipids could be used as a complementary approach to the treatment of patients with chronic liver damage.Keywords
This publication has 67 references indexed in Scilit:
- A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observationsGut, 2006
- Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined dietBiochemical and Biophysical Research Communications, 2004
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology, 2003
- Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosisInternational journal of clinical pharmacology and therapeutics, 2002
- Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspectsJournal of Hepatology, 2001
- Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1Journal of Hepatology, 2001
- Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’Journal of Hepatology, 2001
- Long-term (23 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patientsJournal of Hepatology, 1997
- Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regressionJournal of Hepatology, 1996
- Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cellsLife Sciences, 1996